Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives $37.93 Consensus PT from Analysts

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has earned a consensus rating of “Moderate Buy” from the twelve brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $37.9286.

A number of brokerages recently commented on GMAB. BNP Paribas Exane upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. HC Wainwright decreased their price target on Genmab A/S from $40.00 to $38.00 and set a “buy” rating on the stock in a research report on Thursday, April 30th. The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. Jefferies Financial Group started coverage on Genmab A/S in a research report on Tuesday, February 17th. They issued a “buy” rating and a $41.50 target price on the stock. Finally, Weiss Ratings cut Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of GMAB. CIBC Private Wealth Group LLC grew its position in Genmab A/S by 291.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after acquiring an additional 616 shares during the last quarter. Osaic Holdings Inc. grew its position in Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after acquiring an additional 440 shares during the last quarter. V Square Quantitative Management LLC bought a new position in Genmab A/S in the first quarter valued at about $34,000. NewEdge Advisors LLC grew its position in Genmab A/S by 1,229.0% in the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after acquiring an additional 1,143 shares during the last quarter. Finally, Brown Brothers Harriman & Co. grew its position in Genmab A/S by 143.4% in the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after acquiring an additional 780 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Down 6.3%

Shares of NASDAQ GMAB opened at $23.85 on Friday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18. Genmab A/S has a 52 week low of $20.23 and a 52 week high of $35.43. The stock has a market capitalization of $14.87 billion, a P/E ratio of 18.07, a PEG ratio of 1.51 and a beta of 0.85. The stock’s fifty day moving average is $27.01 and its 200 day moving average is $29.59.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.